Evaluation of anti-cellulite efficacy: a topical cosmetic treatment for cellulite blemishes - a multifunctional formulation.

Cellulite is thought to affect 80-90% of postpubertal women, and is considered much of a cosmetic concern by the large majority of them. In this study, the objective was to assess the efficacy of a topical cosmetic product containing various active ingredients of botanical origin on cellulite blemishes on female volunteers affected by fat accumulations, as well as by slight-to-moderate cellulite in the lower limbs. The assessment was performed by means of various objective evaluations, including contact thermography, morphometric measures of thigh circumference, and microcirculation evaluation. The obtained results indicate that the use of synergistic botanical standardized extracts, through the exploitation of different mechanisms of action and acting on different biological targets, provides visible and measurable results in the improvement of cellulite signs and symptoms.

Nanostructured novel carrier for topical application.

Nanoemulsions have attracted considerable attention in recent years for application in personal care products as potential vehicles for the controlled delivery of cosmetics and the optimized dispersion of active ingredients in particular skin layers. Of the many techniques that have been developed to measure droplet size of emulsions, 2 are of interest: laser light scattering and energy-filtering transmission electron microscopy used to measure the size of droplets in a nanoemulsion formed by a novel emulsifying agent that is able to spontaneously create emulsions with droplet sizes smaller than 300 nm.

Clinical and instrumental assessment of the effects of a new product based on hydroxypropyl chitosan and potassium azeloyl diglycinate in the management of rosacea.

BACKGROUND: Rosacea is a chronic inflammatory skin disease affecting mostly facial skin. Its origin is multifactorial. Important steps in its treatment are avoidance of any triggering factor and control of skin inflammation. AIM: To assess the benefit of topical applications of a new product (P-3075). PATIENTS/METHODS: A randomized, multicenter, double-blind, placebo-controlled, parallel-group, pilot study was carried out to evaluate the efficacy and tolerability of a cream (P-3075) based on 5% potassium azeloyl diglycinate (PAD, Azeloglicina(®)) and 1% hydroxypropyl chitosan (HPCH). Forty-two patients (rosacea stages I and II) were enrolled and randomized, 28 in the P-3075 group and 14 in the placebo group. They were asked to apply the cream twice daily for 4 weeks. The main assessments were the objective quantification of erythema and skin hydration using the Mexameter(®) and Corneometer(®) devices, respectively. Clinical signs and symptoms were evaluated on a four-point scale. RESULTS: The P-3075 cream applied for 28 days was effective in skin protection by reducing erythema, evaluated both instrumentally and clinically. In addition, the clinical assessments of other symptoms such as flushing, stinging, and burning supported the beneficial effect of the P-3075 cream. CONCLUSIONS: The anti-inflammatory and moisturizing effects of potassium azeloyl diglycinate combined with the protective properties of HPCH allow the new product to be a good candidate for controlling signs and symptoms of rosacea.